Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Zemplar; Bulgaria: Zemplar; Czech Republic: Zemplar; Denmark: Zemplar; Estonia: Zemplar; Finland: Zemplar; Germany: Zemplar; Greece: Zemplar; Hungary: Zemplar; Ireland: Zemplar; Italy: Zemplar; Netherlands: Zemplar; Poland: Zemplar; Portugal: Zemplar; Romania: Zemplar; Slovakia: Zemplar; Slovenia: Zemplar; Spain: Zemplar; Sweden: Zemplar; UK: Zemplar.

North America

USA: Zemplar.

Latin America

Argentina: Zemplar; Mexico: Zemplar.

Drug combinations


Paricalcitol: C~27~H~44~O~3~. Mw: 416.64. (1) 19-Nor-1-α,25-dihydroxyvitamin D~2~; (2)(1α.3β,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (3)(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1α,3β,25-triol. CAS-131918-61-1 (1997).

Pharmacologic Category

Vitamins; Vitamin D. (ATC-Code: H05BX02).

Mechanism of action

A synthetic vitamin D analog which binds to and activates vitamin D receptor in kidney, parathyroid gland, intestine and bone, thus reducing parathyroid hormone levels and improving calcium and phosphate homeostasis.

Therapeutic use

Prevention and treatment of secondary hyperparathyroidism associated with stage 3, 4 and 5 chronic kidney disease.

Pregnancy and lactiation implications

Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women.

Unlabeled use


Hypersensitivity to paricalcitol or any component of the formulation. Evidence of vitamin D toxicity. Hypercalcemia.

Warnings and precautions

Excessive vitamin D administration may lead to over-suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures. Chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Use with caution in patients taking cardiac glycosides (digitalis toxicity potentiated by hypocalcemia).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart